140 related articles for article (PubMed ID: 23737087)
1. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
Sanders SL; Agwan S; Hassan M; van Driel ML; Del Mar CB
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009417. PubMed ID: 31446622
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
Turti TV; Baibarina EN; Degtiareva EA; Keshishyan ES; Lobzin YV; Namazova-Вaranova LS; Prodeus AP; Gudkov KM; Kruglova AI; Schulz GA; Notario GF
BMC Res Notes; 2012 Sep; 5():484. PubMed ID: 22943074
[TBL] [Abstract][Full Text] [Related]
5. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
Paes B; Mitchell I; Li A; Lanctôt KL
Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
7. WITHDRAWN: Immunoglobulin treatment for respiratory syncytial virus infection.
Fuller HL; Del Mar CB
Cochrane Database Syst Rev; 2010 Sep; 2010(9):CD004883. PubMed ID: 20824840
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.
McGirr AA; Schwartz KL; Allen U; Solomon M; Sander B
Hum Vaccin Immunother; 2017 Mar; 13(3):599-606. PubMed ID: 27768505
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.
Robbie GJ; Zhao L; Mondick J; Losonsky G; Roskos LK
Antimicrob Agents Chemother; 2012 Sep; 56(9):4927-36. PubMed ID: 22802243
[TBL] [Abstract][Full Text] [Related]
10. A survey of palivizumab for infants with cystic fibrosis in the UK.
McCormick J; Southern KW
Arch Dis Child; 2007 Jan; 92(1):87-8. PubMed ID: 17185451
[No Abstract] [Full Text] [Related]
11. WITHDRAWN: Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children.
Ventre K; Randolph A
Cochrane Database Syst Rev; 2010 May; 2010(5):CD000181. PubMed ID: 20464715
[TBL] [Abstract][Full Text] [Related]
12. Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.
Carroll KN; Griffin MR; Edwards KM; Ali A; Zhu Y; Iwane MK; Szilagyi PG; Staat MA; Stevens TP; Hall CB; Williams JV; Hartert TV
Pediatr Infect Dis J; 2012 Nov; 31(11):e229-31. PubMed ID: 22760537
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis.
Resch B
Open Microbiol J; 2014; 8():71-7. PubMed ID: 25132870
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
Kashiwagi T; Okada Y; Nomoto K
Paediatr Drugs; 2018 Feb; 20(1):97-104. PubMed ID: 28895096
[TBL] [Abstract][Full Text] [Related]
15. Society for Maternal-Fetal Medicine Statement: Clinical considerations for the prevention of respiratory syncytial virus disease in infants.
; Joseph NT; Kuller JA; Louis JM; Hughes BL
Am J Obstet Gynecol; 2024 Feb; 230(2):B41-B49. PubMed ID: 37914061
[TBL] [Abstract][Full Text] [Related]
16. Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection.
Edirisinghe HS; Rajapaksa AE; Royce SG; Sourial M; Bischof RJ; Anderson J; Sarila G; Nguyen CD; Mulholland K; Do LAH; Licciardi PV
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005952
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.
Homaira N; Rawlinson W; Snelling TL; Jaffe A
Int J Pediatr; 2014; 2014():571609. PubMed ID: 25548575
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Disease: An Updated Systemic Review and Meta-Analysis.
El-Atawi K; De Luca D; Ramanathan R; Sanchez Luna M; Alsaedi S; Abdul Wahab MG; Hamdi M; Saleh M
Cureus; 2023 Dec; 15(12):e51375. PubMed ID: 38292946
[TBL] [Abstract][Full Text] [Related]
19. Clinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial Virus.
Utidjian LH; Hogan A; Michel J; Localio AR; Karavite D; Song L; Ramos MJ; Fiks AG; Lorch S; Grundmeier RW
Appl Clin Inform; 2015; 6(4):769-84. PubMed ID: 26767069
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review.
Quinn LA; Shields MD; Sinha I; Groves HE
Syst Rev; 2020 Nov; 9(1):269. PubMed ID: 33239107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
